Responses
Clinical/translational cancer immunotherapy
Original research
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
Compose a Response to This Article
Other responses
No responses have been published for this article.